» Articles » PMID: 31643101

Nonremission and Recurrent Tumor-Induced Osteomalacia: A Retrospective Study

Overview
Date 2019 Oct 24
PMID 31643101
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome. It is curable by excision of the causative tumor. However, a few cases may persist or relapse after tumor resection. We aimed to investigate the rate of these events and related factors. We retrospectively studied TIO patients treated with surgery in a tertiary hospital. TIO was established based on a pathologic examination or the reversion of hypophosphatemia. Refractory TIO patients consisted of those with nonremission or recurrent hypophosphatemia after surgery. A total of 230 patients were confirmed as having TIO. After primary surgery, 26 (11.3%) cases persisted, and 16 (7.0%) cases recurred. The overall refractory rate was 18.3%. The median time of recurrence was 33 months. Compared with patients in the recovery group, patients in the refractory group were more likely to be female (59.5% versus 41.0%, p = .029) and have a lower serum phosphate level (0.44 ± 0.13 versus 0.50 ± 0.11 mmol/L, p = .002). The refractory rate was lowest in head/neck tumors (7.5%) and highest in spine tumors (77.8%). Regarding the tissue involved of tumor location, the refractory rate was higher in tumors involving bone than tumors involving soft tissue (32.7% versus 7.0%, p < .001). The outcomes of malignant tumors were worse than those of benign tumors (p < .001): nonremission rate, 21.4% versus 9.7%; recurrence rate, 28.6% versus 6.5%. In the multivariate regression analysis, female sex, spine tumors, bone tissue-involved tumors, malignancy, and low preoperation serum phosphorus levels were identified as risk factors for refractory outcomes. High preoperative fibroblast growth factor 23 (FGF23) levels were also associated with refractory after adjusting for involving tissue and tumor malignancy. In summary, we are the first to report the rate and clinical characteristics of refractory TIO in a large cohort. For patients with multiple risk factors, especially spine tumors, clinical practitioners should be aware of a poor surgical prognosis. © 2019 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.

Citing Articles

Treatment Advances in Tumor-Induced Osteomalacia.

Hartley I, Roszko K Calcif Tissue Int. 2025; 116(1):24.

PMID: 39755803 PMC: 11700048. DOI: 10.1007/s00223-024-01317-x.


MiR-331-3p facilitates osteoporosis and may promote osteoporotic fractures by modulating NRP2 expression.

Na C, Ao D, Chen H J Orthop Surg Res. 2024; 19(1):487.

PMID: 39154011 PMC: 11330005. DOI: 10.1186/s13018-024-04959-7.


Clinical characteristics and surgical outcomes of vertebral lesions associated with tumor-induced osteomalacia: report of 16 patients and review of the literature.

Pang Q, Zhou R, Ni X, Liu Y, Jin J, Wu H Osteoporos Int. 2024; 35(11):1951-1962.

PMID: 39093437 PMC: 11499524. DOI: 10.1007/s00198-024-07178-2.


Long-Term Follow-Up Data of Tumor-Induced Osteomalacia Managed with Surgery and/or Radiofrequency Ablation from a Single Center.

Memon S, Patel M, Lila A, Jadhav S, Sarathi V, Karlekar M Calcif Tissue Int. 2024; 115(3):242-250.

PMID: 38922426 DOI: 10.1007/s00223-024-01249-6.


Orthopedic Surgical Treatment of Patients with Tumor-induced Osteomalacia Located in the Hip Bones: A Retrospective Analysis of 10 Years in a Single Center.

Liu S, Zhou X, Liang A, Xing J, Liu Y, Jin J Orthop Surg. 2024; 16(8):1871-1883.

PMID: 38887173 PMC: 11293914. DOI: 10.1111/os.14105.


References
1.
Sun Z, Jin J, Qiu G, Gao P, Liu Y . Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet Disord. 2015; 16:43. PMC: 4349610. DOI: 10.1186/s12891-015-0496-3. View

2.
Folpe A, Fanburg-Smith J, Billings S, Bisceglia M, Bertoni F, Cho J . Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004; 28(1):1-30. DOI: 10.1097/00000478-200401000-00001. View

3.
Endo I, Fukumoto S, Ozono K, Namba N, Inoue D, Okazaki R . Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J. 2015; 62(9):811-6. DOI: 10.1507/endocrj.EJ15-0275. View

4.
Imel E, Peacock M, Pitukcheewanont P, Heller H, Ward L, Shulman D . Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2006; 91(6):2055-61. DOI: 10.1210/jc.2005-2105. View

5.
Kane S, Kakkar A, Oza N, Sridhar E, Pai P . Phosphaturic mesenchymal tumor of the nasal cavity and paranasal sinuses: A clinical curiosity presenting a diagnostic challenge. Auris Nasus Larynx. 2017; 45(2):377-383. DOI: 10.1016/j.anl.2017.05.006. View